2017-11-08
Ark Biosciences and Calibr Announce Joint Development of First-in-Class Chronic Obstructive Pulmonary Disease Drug
Ark announced a collaboration with the Calibr to jointly develop novel first-in-class drugs for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and related lung diseases...
know more >